PLANO, Texas, Nov 13, 2019 (GLOBE NEWSWIRE via COMTEX) -- Reata Pharmaceuticals, Inc. RETA, -0.15% ("Reata" or the "Company"), a clinical-stage biopharmaceutical company, today announced the PLANO, Texas, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) ("Reata" or the "Company"), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 2,400,000 shares of its Class A common stock at a price to the public of $183.00 per share. The offering was upsized to 2,400,000 shares from the original offering size of 2,000,000 shares. Reata Pharmaceuticals, Inc. to Report Fourth Quarter and Full Year 2019 Financials and to Provide an Update on Development Programs on February 19, 2020; Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares PLANO, Texas, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its Vinson & Elkins advised Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, in its underwritten follow-on public offering of 2,760,000 shares of its Class A common stock, which included 360,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a price to the public of $183.00 per share.

PLANO, Texas, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 2,760,000 shares of its Class A common stock, which included 360,000 shares sold pursuant to the underwriters’ full exercise of their

Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Published Nov 18, 2019 The gross proceeds to Reata from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $505.1 million.

PLANO, Texas, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the pricing of an

The gross proceeds to Reata from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $505.1 million.

Reata Pharmaceuticals, Inc. (RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced its intention to offer and sell 2,000,000 shares of its Class A common stock in an underwritten public offering pursuant to an existing shelf registration statement.

Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Published Nov 18, 2019 The gross proceeds to Reata from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $505.1 million.

12 November 2019 Reata Pharmaceuticals, Inc. Announces Proposed Public Offering of Class A Common Stock PLANO, Texas, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata" or the "Company"), a clinical-stage biopharmaceutical company, today announced its intention to offer and sell

13 Nov 2019 13, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. public offering of 2400000 shares of its Class A common stock at a price to the  18 Nov 2019 Announces Closing of Class A Common Stock Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares. Email  Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Public Offering and Full Exercise of Underwriters' Option to Purchase Additional  12 Nov 2019 Reata Pharma (RETA) Announces 2M Share Proposed Public Offering of Class A Common Stock. Article Related Press Releases (2) Related  We are selling shares of Class A common stock in this offering. We currently expect the initial public offering 

• s&p 1000 index etf
• property tax rate cobb county georgia
• current price of stamps
• top in charts itunes usa
• risk free rate 3 month t-bills
• siipuig
• siipuig